(Q37290088)

19 August 2017

1 reference

title

Epaxal: a virosomal vaccine to prevent hepatitis A infection (English)

1 reference

19 August 2017

1 reference

1 reference

Patrick A Bovier

1

1 reference

19 August 2017

1 October 2008

1 reference

Expert Review of Vaccines

19 August 2017

1 reference

19 August 2017

7

1 reference

19 August 2017

8

1 reference

19 August 2017

1141-1150

1 reference

Epidemiology and prevention of hepatitis A in travelers

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

History and epidemiology of hepatitis A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Incidence of hepatitis A in Israel following universal immunization of toddlers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Incidence of hepatitis A in the United States in the era of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Control of hepatitis A by universal vaccination of adolescents, Puglia, Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Control of hepatitis A through routine vaccination of children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

From hepatitis B to hepatitis A and B prevention: the Puglia (Italy) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Immune responses of anti-HAV in children vaccinated with live attenuated and inactivated hepatitis A vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

New technology platforms in the development of vaccines for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Influenza virosomes as an efficient system for adjuvanted vaccine delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Virosomal adjuvanted antigen delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Hepatitis A vaccines and the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal®)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Rapid antibody response after vaccination with a virosomal hepatitis a vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Control of a Hepatitis A Outbreak by Active Immunization of High-Risk Susceptible Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Efficacy of Virosome Hepatitis A Vaccine in Young Children in Nicaragua: Randomized Placebo‐Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Long-term immunogenicity of an inactivated virosome hepatitis A vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Hepatitis A booster vaccination: is there a need?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.8.1141

10.1586/14760584.7.8.1141

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18844588